Tingting Cui
Associate Director AstraZeneca
Work on process development for different modalities, antibody, bispecific, ADC, pDNA, mRNA, now working on establish bioconjugation platform within BPD
Seminars
Wednesday 10th March 2027
A Scalable Lysine Bioconjugation Platform: Reducing Development Burden as Clinical Demand Scales
3:30 pm
- Presenting quality-based driven development
- Showcasing platform establishment
- Leveraging multiple programme efficiency
